Teva Adds 40th Drug to Contract Pharmacy Restriction Policy

Teva added a biosimilar of AbbVie's blockbuster Humira to its list of products included in its 340B contract pharmacy restrictions.
Teva Pharmaceuticals recently added the 40th drug to the list of medications included in its contract pharmacy policy restrictions for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Breaking News

Appeals Court Approves Drugmakers’ Federal 340B Contract Pharmacy Restrictions But Leaves Open Possibility of Enforcement Against Stricter Policies

A federal appeals court decided that the 340B statute does not prohibit all types of restrictions on 340B contract pharmacy use.
A federal appeals court today decided that the 340B statute does not prohibit drugmakers from placing conditions on the distribution [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Minnesota Legislature Clears Contract Pharmacy Access Bill But Enforcement Measures Dropped At Last Moment

The Minnesota legislature passed a bill from state Rep. Dave Lislegard (D) to bar 340B drugmaker contract pharmacy restrictions in the state.
Shortly before adjourning, the Minnesota legislature cleared and sent to the governor legislation to bar 340B contract pharmacy access restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities

Drugmaker Novo Nordisk is providing refunds to 340B covered entities on its blockbuster diabetes/weight loss drug Ozempic and three other products.
Drugmaker Novo Nordisk announced it is providing 340B covered entities 12-months-worth of refunds on four drug products including two of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Virginia Governor Vetoes 340B Contract Pharmacy Access Law that Nearly Unanimously Passed State Legislature

Virginia Gov. Glenn Youngkin (R) vetoed 340B contract pharmacy access legislation after the state senate rejected his proposed amendment.
Virginia Gov. Glenn Youngkin (R) late Friday vetoed a bill that would have prohibited drugmaker contract pharmacy restrictions on grantee [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Maryland Is Sixth State to Enact 340B Contract Pharmacy Access Law

Maryland Gov. Wes Moore (right) will make Maryland the sixth state to prohibit drugmaker 340B contract pharmacy restrictions when he signs legislation today.
Maryland Gov. Wes Moore (D) this morning is signing legislation to make Maryland the sixth state to prohibit drugmaker 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CVS Cites 340B Contract Pharmacy Restrictions in 19% Income Drop in Its Pharmacy Services

CVS Health said drugmaker 340B contract pharmacy restrictions contributed to a decline in the company's pharmacy services revenue.
CVS Health recently cited drug manufacturers’ contract pharmacy restrictions as one of the causes for a 19% year-over-year income decline [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Court Sets April 2025 Trial for AstraZeneca’s Arkansas 340B Law Challenge Amid State Enforcement Actions

The trial for drugmaker AstraZeneca's lawsuit against Arkansas' 340B contract pharmacy access law will take place in April 2025.
A federal judge scheduled an April 2025 trial date for AstraZeneca’s lawsuit against Arkansas’ 340B contract pharmacy access law as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds 

Analysts from IQVIA found that 340B wholesale acquisition cost sales increased by 17% from 2022 to 2023.
The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health System Appeal of False Claims Suit Against Drugmakers For Alleged 340B Overcharges Allowed to Move Forward

California-based health system Adventist Health System/West's lawsuit alleging drugmaker 340B overcharges was allowed to move forward in a federal appeals court.
A California health system’s lawsuit alleging “hundreds of millions” in overcharges by four drugmakers was recently released from required mediation [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live